Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment

Cho Soo-Kyung; Kim Dam; Won Soyoung; Han Minkyung; Lee Jiyoung; Jang Eun Jin; Kim Tae-Hyung; Bae Sang-Cheol; Sung Yoon-Kyoung

首页> 外文期刊>Seminars in Arthritis and Rheumatism >Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment

【24h】

Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment

机译：抗TNF治疗后开发结核病患者的生物DMARD的安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: To estimate the incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients treated with tumor necrotizing factor inhibitor (TNFI) and evaluate the safety of resuming biologic disease modifying anti-rheumatic drugs (DMARDs) in patients who developed TB after anti TNF treatment.

机译：目的：估算用肿瘤坏死因子抑制剂（TNFI）治疗的类风湿性关节炎（RA）患者的结核病（RB）的发病率，并评估恢复生物疾病修饰抗风湿药物（DMARDS）的安全性抗议者 TNF治疗。

著录项

来源
《Seminars in Arthritis and Rheumatism》 |2017年第1期|共6页
作者
Cho Soo-Kyung; Kim Dam; Won Soyoung; Han Minkyung; Lee Jiyoung; Jang Eun Jin; Kim Tae-Hyung; Bae Sang-Cheol; Sung Yoon-Kyoung;
展开▼
作者单位

Hanyang Univ Hosp Rheumat Dis Hosp Rheumat Dis Seoul South Korea;

Hanyang Univ Hosp Rheumat Dis Hosp Rheumat Dis Seoul South Korea;

CRCRA Seoul South Korea;

CRCRA Seoul South Korea;

CRCRA Seoul South Korea;

Andong Natl Univ Dept Informat Stat Andong Si South Korea;

Hanyang Univ Guri Hosp Div Pulm &

Crit Care Med Guri Si South Korea;

Hanyang Univ Hosp Rheumat Dis Hosp Rheumat Dis Seoul South Korea;

Hanyang Univ Hosp Rheumat Dis Hosp Rheumat Dis Seoul South Korea;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词
Rheumatoid arthritis; Tuberculosis; TNF inhibitor; Biologic DMARDs;

机译：类风湿性关节炎;结核;TNF抑制剂;生物学DMARDS;

相似文献

外文文献
中文文献
专利

1. Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment [J] . Cho Soo-Kyung, Kim Dam, Won Soyoung, Seminars in Arthritis and Rheumatism . 2017,第1期

机译：抗TNF治疗后开发结核病患者的生物DMARD的安全性
2. ECONOMIC IMPACT OF BIOLOGIC DMARD TREATMENT FOR APCA AND RF PATIENTS: A COMPARISON OF ABATACEPT AND TNFI BIOLOGIC DMARDS [J] . Shafrin J., Tebeka M., Price K., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：生物学DMARD治疗APCA和RF患者的经济影响：ABATACEPT和TNFI生物DMARD的比较
3. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. [J] . Soliman MM, Ashcroft DM, Watson KD, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2011,第4期

机译：类风湿关节炎患者同时使用DMARDs对抗TNF治疗的持久性的影响：英国风湿病生物学学会的注册结果。
4. Label-Free Quantitative Proteomics Profiling of Human Osteoclast Activation, Differentiation and anti-TNF Biologics Treatment [C] . Chenqi Hu, Bohdan Harvey, Zehra Kaymakcalan, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：无标签定量蛋白质组学分析人骨骨骨骨激活，分化和抗TNF生物制剂治疗
5. Patient Characteristics and Treatment Outcomes Among Tuberculosis Patients in Sierra Leone. [D] . Sesay, Mohamed Lamin. 2017

机译：塞拉利昂结核病患者的患者特征和治疗结果。
6. Comment on ‘Less educated and older patients have reducedaccess to biologic DMARDs even in a country with highly developed social welfare(Norway): results from Norwegian cohort Study NOR-DMARD’ [O] . EM Dennison, KA Jameson, J Marks, -1

机译：评论受过良好教育且年龄较大的患者减少了即使在社会福利高度发达的国家也可以使用生物DMARD（挪威）：挪威队列研究NOR-DMARD的结果
7. FRI0092 SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) [O] . Mark C. Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg, 2019

机译：Fri0092 Frivootinib在活性类风湿性关节炎中的安全性和有效性通过先前的生物DMARD在患者对生物DMARD（BDMARD-IR）的不容忍（BDMARD-IR）

Safety of resuming biologic DMARDs in patients who develop tuberculosis after anti-TNF treatment

摘要

著录项

相似文献

相关主题

期刊订阅